secondary immunization

Summary

Summary: Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.

Top Publications

  1. ncbi Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
    Inese Cebere
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    Vaccine 24:417-25. 2006
  2. ncbi Requirement for CD4 T cell help in generating functional CD8 T cell memory
    Devon J Shedlock
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Science 300:337-9. 2003
  3. pmc Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection
    Yasushi Miyahira
    Atopy Research Center, Department of Parasitology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Infect Immun 73:7356-65. 2005
  4. ncbi The success and failure of BCG - implications for a novel tuberculosis vaccine
    Peter Andersen
    Statens Serum Institute, Department of Infectious Disease Immunology, Artillerivej 5, 2300 Copenhagen S, Denmark
    Nat Rev Microbiol 3:656-62. 2005
  5. ncbi Jump-starting the immune system: prime-boosting comes of age
    David L Woodland
    Trudeau Institute, 154 Algonquin Ave, Saranac Lake, NY 12983, USA
    Trends Immunol 25:98-104. 2004
  6. ncbi Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens
    David M Asmuth
    Division of Infectious Disease, Department of Internal Medicine, University of California at Davis, Sacramento, CA 95618, USA
    J Infect Dis 201:132-41. 2010
  7. ncbi Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response
    I Ramos
    Centro de Investigaciones Biologicas, Spanish Research Council, Ramiro de Maeztu 9, 28040 Madrid, Spain
    Vaccine 26:333-44. 2008
  8. pmc A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge
    S J Dunachie
    University of Oxford, Nuffield Department of Clinical Medicine, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Rd, Headington, Oxford OX3 7LJ, United Kingdom
    Infect Immun 74:5933-42. 2006
  9. ncbi Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus
    T M Herremans
    Research Laboratory for Infectious Diseases, National Institute of Public Health and the Environment RIVM, Bilthoven, The Netherlands
    J Immunol 162:5011-8. 1999
  10. ncbi Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis
    Jun Wang
    Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Centre for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    J Immunol 173:6357-65. 2004

Detail Information

Publications205 found, 100 shown here

  1. ncbi Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
    Inese Cebere
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    Vaccine 24:417-25. 2006
    ..HIVA DNA and MVA.HIVA vaccines either alone or in a prime-boost regime to healthy HIV-1/2-negative adults indicated that the vaccines were safe and warranted further testing of this approach in larger phase I/II studies...
  2. ncbi Requirement for CD4 T cell help in generating functional CD8 T cell memory
    Devon J Shedlock
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Science 300:337-9. 2003
    ..These results demonstrate a previously undescribed role for CD4 help in the development of functional CD8 memory...
  3. pmc Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection
    Yasushi Miyahira
    Atopy Research Center, Department of Parasitology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Infect Immun 73:7356-65. 2005
    ..cruzi. These results indicated, for the first time, that the induction of immune responses against a single CD8+-T-cell epitope derived from an intrinsic T. cruzi antigen was sufficient to control lethal T. cruzi infection...
  4. ncbi The success and failure of BCG - implications for a novel tuberculosis vaccine
    Peter Andersen
    Statens Serum Institute, Department of Infectious Disease Immunology, Artillerivej 5, 2300 Copenhagen S, Denmark
    Nat Rev Microbiol 3:656-62. 2005
    ..Here, we discuss the potential mechanisms behind the variation of BCG efficacy and their implications for an improved TB vaccination strategy...
  5. ncbi Jump-starting the immune system: prime-boosting comes of age
    David L Woodland
    Trudeau Institute, 154 Algonquin Ave, Saranac Lake, NY 12983, USA
    Trends Immunol 25:98-104. 2004
    ..This Review discusses the impact of these recent developments on the future of prime-boost vaccine strategies...
  6. ncbi Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens
    David M Asmuth
    Division of Infectious Disease, Department of Internal Medicine, University of California at Davis, Sacramento, CA 95618, USA
    J Infect Dis 201:132-41. 2010
    ..We report composite results from the Merck phase I program of near-consensus clade B human immunodeficiency virus (HIV) type 1 gag vaccines...
  7. ncbi Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response
    I Ramos
    Centro de Investigaciones Biologicas, Spanish Research Council, Ramiro de Maeztu 9, 28040 Madrid, Spain
    Vaccine 26:333-44. 2008
    ....
  8. pmc A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge
    S J Dunachie
    University of Oxford, Nuffield Department of Clinical Medicine, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Rd, Headington, Oxford OX3 7LJ, United Kingdom
    Infect Immun 74:5933-42. 2006
    ..033). No protection was observed in the DDM-CS group. Prime-boost vaccination with DNA and MVA encoding ME-TRAP but not CS resulted in partial protection against P. falciparum sporozoite challenge in the present study...
  9. ncbi Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus
    T M Herremans
    Research Laboratory for Infectious Diseases, National Institute of Public Health and the Environment RIVM, Bilthoven, The Netherlands
    J Immunol 162:5011-8. 1999
    ..It is concluded that IPV vaccination alone is insufficient to induce a mucosal IgA response against poliovirus. In mucosally (OPV-) primed individuals, however, booster vaccination with IPV leads to a strong mucosal IgA response...
  10. ncbi Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis
    Jun Wang
    Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Centre for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    J Immunol 173:6357-65. 2004
    ..Our study also lends strong evidence that respiratory mucosal vaccination is critically advantageous over systemic routes of vaccination against TB...
  11. pmc Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein
    Michael Walther
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, United Kingdom
    Infect Immun 74:2706-16. 2006
    ..Vaccines containing this antigen proved safe and induced modest immune responses but showed no evidence of efficacy in a sporozoite challenge...
  12. pmc Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination
    Bruna C G de Alencar
    Centro Interdisciplinar de Terapia Gênica CINTERGEN, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Rua Mirassol 207, Sao Paulo, SP 04044 010, Brazil
    Infect Immun 77:4383-95. 2009
    ..Our study thus demonstrated a role for perforin and IFN-gamma in a number of T-cell-mediated effector functions and in the antiparasitic immunity generated by a heterologous plasmid DNA prime-adenovirus boost vaccination strategy...
  13. ncbi Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants
    David FitzSimons
    World Health Organization, Via Appia 20, CH 1211 Geneva, Switzerland
    Vaccine 23:4158-66. 2005
    ..The main focus was on universal vaccination programmes with data being presented from Italy, Saudi Arabia, Singapore, Spain, Taiwan, Thailand, The Gambia, and USA (Alaska)...
  14. ncbi Long-term protection of hepatitis B vaccine 18 years after vaccination
    Faleh Alfaleh
    Department of Medicine, College of Medicine, King Saud University, P O Box 2925 59, Riyadh 11461, Saudi Arabia
    J Infect 57:404-9. 2008
    ..This is the third evaluation study of the hepatitis B virus (HBV) vaccination program, initiated in 1989 in Saudi Arabia...
  15. ncbi Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
    J Schneider
    Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
    Nat Med 4:397-402. 1998
    ..DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells...
  16. ncbi Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    R R Amara
    Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, Atlanta, GA 30329, USA
    Science 292:69-74. 2001
    ..These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic...
  17. ncbi Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid
    Masanori Matsui
    Department of Microbiology, Saitama Medical School, Moroyama cho, Iruma gun, 350 0495, Saitama, Japan
    Vaccine 21:1629-39. 2003
    ..Thus, the prime-double boosts immunization together with IL-12 may be promising for HCV vaccine...
  18. ncbi IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection
    Carmel B Stober
    Cambridge Institute for Medical Research, University of Cambridge, United Kingdom
    J Immunol 175:2517-24. 2005
    ..Anti-IL-10R treatment in vivo demonstrated that IL-10 was functional in determining vaccine failure, rendering LACK protective in the presence of high IFN-gamma/low IL-5 responses...
  19. ncbi Progress in DNA-based heterologous prime-boost immunization strategies for malaria
    Anne C Moore
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Immunol Rev 199:126-43. 2004
    ..We summarize the preclinical design and development of these heterologous prime-boost vaccines and discuss the encouraging results that have been observed in vaccinated humans...
  20. pmc Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination
    Wolfgang Kastenmuller
    Institute of Molecular Virology, Antigen specific Immunotherapy Clinical Cooperation Group, National Research Center for Environment and Health, 81675 Munich, Germany
    J Exp Med 204:2187-98. 2007
    ..Our findings provide a basis for novel strategies for how boost vaccination to defined antigens can be selectively improved. They give important new insights into the design of more efficient poxviral vectors for immunotherapy...
  21. ncbi Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men
    E B Imoukhuede
    MRC Laboratories, Banjul, Gambia
    Vaccine 24:6526-33. 2006
    ..This level of effector T-cell responses appears higher than that seen in previously reported studies of CS-based candidate malaria vaccines...
  22. pmc Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules
    George T Mercier
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, TX, USA
    Vaccine 25:8687-701. 2007
    ....
  23. ncbi Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults
    Richarda M de Voer
    Laboratory for Infectious Diseases and Screening, National Institute of Public Health and the Environment, 3720 BA Bilthoven, The Netherlands
    Vaccine 27:6974-82. 2009
    ..the kinetics of isotype-specific antibodies in adults (n=21) after primary immunization with MenCC or secondary immunization with MenCC or plain MenC polysaccharide vaccine...
  24. pmc Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
    Daniel P Webster
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    Proc Natl Acad Sci U S A 102:4836-41. 2005
    ....
  25. pmc Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis
    Michael Santosuosso
    Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Center for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    Infect Immun 74:4634-43. 2006
    ..Our study demonstrates that intranasal administration of AdAg85A represents an effective way to boost immune protection by parenteral BCG vaccination...
  26. ncbi Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells
    Daniela Frölich
    Department of Medicine, Rheumatology, and Clinical Immunology, Charite University Medicine Berlin, Germany
    J Immunol 185:3103-10. 2010
    ..The data indicate that although following secondary immunization PCs can derive from memory B cells without further somatic hypermutation, in some circumstances, likely ..
  27. pmc Vaccine coverage levels after implementation of a middle school vaccination requirement, Florida, 1997-2000
    Kieran J Fogarty
    Epidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention CDC, 1600 Clifton Rd, MS E 52, Atlanta, GA 30333, USA
    Public Health Rep 119:163-9. 2004
    ..This study examined coverage levels among students entering seventh grade in Florida following implementation of a school entry vaccination requirement in 1997...
  28. ncbi Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 172:6290-7. 2004
    ..Moreover, these studies suggest that using Ad vectors derived from immunologically distinct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-existing anti-Ad immunity...
  29. pmc Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs
    Yuuei Shu
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Vaccine 25:1398-408. 2007
    ....
  30. pmc Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis
    T Mark Doherty
    Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark
    Infect Immun 70:3111-21. 2002
    ....
  31. ncbi Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, DK 2300 Copenhagen, Denmark
    J Immunol 177:6353-60. 2006
    ..tb in LTK63/Ag85B-ESAT-6-boosted mice, compared with BCG-vaccinated animals. Thus, LTK63/Ag85B-ESAT-6 represents an efficient preventive vaccine against tuberculosis with a strong ability to boost prior BCG immunity...
  32. ncbi Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nature 424:681-4. 2003
    ..This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses...
  33. pmc A middle school immunization law rapidly and substantially increases immunization coverage among adolescents
    Francisco Averhoff
    National Immunization Program, MS E 61, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Am J Public Health 94:978-84. 2004
    ..This study assessed the effectiveness of a middle school vaccination requirement for raising second-dose measles, mumps, and rubella vaccine and hepatitis B vaccine coverage among adolescents...
  34. ncbi Prime-boost immunisation strategies for tuberculosis
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Microbes Infect 7:962-7. 2005
    ..Using BCG as the priming immunisation in such a heterologous prime-boost strategy is a practical solution, which allows the beneficial effects of BCG in children to be maintained...
  35. ncbi Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coli
    M O Lasaro
    Microbiology Department, Biomedical Science Institute, University of Sao Paulo, Av Prof Lineu Prestes 1374, Sao Paulo 05508 000, Brazil
    Vaccine 23:2430-8. 2005
    ....
  36. ncbi Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea
    B Genton
    Papua New Guinea Institute of Medical Research, Goroka and Maprik, Papua New Guinea
    Vaccine 18:2504-11. 2000
    ..The vaccine induced good cellular responses, especially for MSP1 and RESA. Boosting of humoral responses was weak, probably because of high baseline antibody levels...
  37. ncbi Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope
    Christina M Ryan
    Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA
    J Immunol 177:255-67. 2006
    ..These results indicate that epitope V provides a target for CD8+ T cells against spontaneous tumors in vivo, and suggests that epitopes with similar properties can be harnessed for tumor immunotherapy...
  38. ncbi A review of the long-term protection after hepatitis A and B vaccination
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department of Epidemiology and Social Medicine, University of Antwerp, Belgium
    Travel Med Infect Dis 5:79-84. 2007
    ....
  39. pmc Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations
    Martha Sedegah
    Malaria Program, Naval Medical Research Center, Silver Spring, Maryland 20910 7500, USA
    Infect Immun 70:3493-9. 2002
    ..These results demonstrate that a heterologous priming and boosting vaccination can provide lasting protection against malaria in this model system...
  40. pmc An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis
    Laleh Majlessi
    Biologie des Régulations Immunitaires, INSERM, E 352, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France
    Infect Immun 74:2128-37. 2006
    ..These results question the broadly admitted correlation between the frequency of IFN-gamma-producing CD4+ T cells and the level of protection against tuberculosis...
  41. pmc Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins
    Gillis R Otten
    Chiron Corporation, 4560 Horton St, Mail Stop 4 3, Emeryville, California 94608, USA
    J Virol 79:8189-200. 2005
    ....
  42. ncbi Polio extraimmunization in children younger than 2 years after changes in immunization recommendations
    Loren K Mell
    Center for Health Studies, Group Health Cooperative, Seattle, Washington, USA
    Pediatrics 111:296-301. 2003
    ..To investigate trends over time in polio extraimmunization among children in 4 large health maintenance organizations and to study the association with recent changes in polio immunization policy...
  43. ncbi Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men
    Vasee S Moorthy
    Medical Research Council Laboratories, Banjul, Gambia
    J Infect Dis 189:2213-9. 2004
    ..These results highlight optimized combination regimens with general relevance to the development of vaccines targeting intracellular pathogens...
  44. ncbi Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA
    H J Mollenkopf
    Max Planck Institute for Infection Biology, Department of Immunology, Schumannstr 21 22, 10117 Berlin, Germany
    Vaccine 19:4028-35. 2001
    ..Vaccination with a single dose of r S. typhimurium secreting ESAT-6 reduced numbers of tubercle bacilli in the lungs throughout the course of infection. The combined prime-boost vaccination did not considerably enhance protection...
  45. pmc Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence
    Marianne A B van der Sande
    Medical Research Council Laboratories, Fajara, The Gambia
    PLoS ONE 2:e753. 2007
    ..These children are now in adolescence and approaching adulthood, when the onset of sexual activity may challenge their hepatitis B immunity. Thus a booster dose in adolescence could be important to maintain long-term protection...
  46. pmc Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization
    Wentao Gao
    Department of Surgery and Medicine, University of Pittsburgh School of Medicine, Molecular Medicine Institute, Suite 412, 300 Technology Drive, Pittsburgh, PA 15219, USA
    J Virol 80:1959-64. 2006
    ....
  47. pmc Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge
    N A Doria-Rose
    Seattle Biomedical Research Institute, University of Washington, Seattle, Washington 98109, USA
    J Virol 77:11563-77. 2003
    ..03). We conclude that multigene vaccines delivered by a combination of vaccinia virus and gene gun-delivered DNA were effective against SHIV89.6P viral challenge in M. nemestrina...
  48. ncbi Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low
    Elizabeth H Boxall
    Health Protection Agency, West Midlands Public Health Laboratory, Heartlands Hospital, Birmingham, United Kingdom
    J Infect Dis 190:1264-9. 2004
    ..The long-term response to hepatitis B vaccination during infancy has not been fully evaluated in countries where endemicity is low...
  49. ncbi Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
    John J Treanor
    Department of Medicine, University of Rochester, Rochester, NY, USA
    N Engl J Med 354:1343-51. 2006
    ..Influenza A (H5N1) viruses could cause a severe worldwide epidemic, with high attack rates, large numbers of deaths and hospitalizations, and wide disruption. Effective vaccines against these viruses in humans are urgently needed...
  50. ncbi Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A
    Douglas S Walsh
    Department of Immunology and Medicine, US Army Medical Component, Armed Forces Research Institute of Medical Sciences AFRIMS, Bangkok, Thailand
    Vaccine 24:4167-78. 2006
    ..In field studies, RTS,S/AS02A reduced malaria infection, clinical episodes, and disease severity. Heterologous prime-boost immunization regimens, optimally spaced, might improve the protective immunity of RTS,S/AS02A...
  51. pmc The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis
    Claire Swetman Andersen
    Staten Serum Institute, TB Vaccine Research, Department of Infectious Disease Immunology, 5 Artillerivej, DK 2300 Copenhagen S, Denmark
    Infect Immun 75:408-16. 2007
    ..Thus, the results demonstrate the effectiveness of mucosal vaccination with Ag85B-ESAT-6 mixed with CTA1-DD/ISCOMs as adjuvant for stimulating TB-specific protective immunity in the lung...
  52. ncbi Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth
    M J Saffar
    Pediatric Infectious Diseases Ward, Department of Pediatrics Mazandaran Medical Sciences University, Boalisina Hospital, Pasdaran Boulevard, Sari Iran
    Indian Pediatr 41:1232-7. 2004
    ..Although nearly 42% of them were not seroprotected, but most of boosted subjects (87.3%) retained robust immunologic memory and rapidly retained a protective anti-HBs antibody titer of at least 10 IU/L after booster vaccination...
  53. pmc Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis
    H McShane
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    Infect Immun 69:681-6. 2001
    ....
  54. ncbi The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection
    S Coulibaly
    Baxter Vaccine AG, Biomedical Research Center, Uferstrasse 15, A 2304 Orth Donau, Austria
    Virology 341:91-101. 2005
    ..Similar to MVA, prime-boost immunizations with defective vaccinia induced robust long-term immunity, suggesting it as a promising next generation smallpox vaccine...
  55. ncbi The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge
    S Mendez
    Laboratory of Parasitic Diseases and Laboratory of Clinical Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 166:5122-8. 2001
    ..These data suggest that under conditions of natural challenge, DNA vaccination has the capacity to confer complete protection against cutaneous leishmaniasis and to prevent the establishment of infection reservoirs...
  56. pmc A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
    Cristina Giambi
    Communicable Disease Epidemiology Unit, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
    BMC Infect Dis 8:100. 2008
    ..The objectives of this study were to evaluate the persistence of antibodies to anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B vaccine...
  57. ncbi Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers
    Annarosa Floreani
    Department of Surgical and Gastroenterological Sciences, University of Padua, Via Giustiniani 2, 35128 Padua, Italy
    Vaccine 22:607-10. 2004
    ..Overall, the anti-HBs seroprotection rate was 95.4% (102 subjects). Based on GMT results, no booster dose is necessary in healthy adults for at least 10 years after primary immunization...
  58. ncbi Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose
    J Wiström
    Department of Infectious Diseases, University Hospital of Umea, Sweden
    Vaccine 17:2162-5. 1999
    ..In conclusion, one single dose of HB vaccine seemed to confer on young healthy individuals a well preserved B cell memory, disclosed as a rapid and strong antibody response to a second dose four years later...
  59. ncbi Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country
    Bernard Duval
    Institut National de Sante Publique du Quebec, Quebec, Canada
    Pediatr Infect Dis J 24:213-8. 2005
    ..The long term effect of the booster dose in teenagers is unknown. We evaluated the immunogenicity of 2 pediatric hepatitis vaccines after primary vaccination and after a booster dose...
  60. ncbi Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus
    Richard J Anderson
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Immunol 172:3094-100. 2004
    ..berghei and was more immunogenic and protective than DNA/MVA prime/boost immunization. However, further improvement was not achieved by sequential (triple) immunization with a DNA vaccine, FP9, and MVA...
  61. ncbi Recent developments in tuberculosis vaccines
    Melles Haile
    Department of Bacteriology, Swedish Institute for Infectious Disease Control, Solna, Sweden
    Curr Opin Infect Dis 18:211-5. 2005
    ..Some new TB vaccines, which have entered or are expected to enter clinical trials, are highlighted...
  62. ncbi A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life
    Salvacion Gatchalian
    Research Institute for Tropical Medicine, Filinvest Corporate Centre, Alabang, Muntinlupa City, Manila, Philippines
    Hum Vaccin 4:60-6. 2008
    ..Combined DTPw-HBV and DTPw-HBV/Hib vaccines using new vaccine antigen sources will promote continued supply of combined DTPw-based vaccines to global mass vaccination campaigns...
  63. ncbi Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years
    Laura L Hammitt
    Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, AK, USA
    Vaccine 25:6958-64. 2007
    ..These children had protective anti-HBs concentrations when tested after receiving a three-dose series of 2.5 microg recombinant hepatitis B vaccine starting at birth...
  64. ncbi Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine
    B Watson
    Albert Einstein Medical Center and The Philadelphia Department of Health, Division of Disease Control, Immunization Program, 500 S Broad Street, Philadelphia, PA 19146, USA
    Vaccine 19:3164-8. 2001
    ..Significantly even the 5 individuals with less than 10 mIU/ml of anti-HBs prior to the booster all had impressive responses to the booster dose...
  65. ncbi A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America
    Miguel Tregnaghi
    Centro de Desarrollo de Proyectos Avanzados, Cordoba, Argentina
    Rev Panam Salud Publica 19:179-88. 2006
    ....
  66. pmc Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice
    Carmel B Stober
    Cambridge Institute for Medical Research, Wellcome Trust MRC Building, Addenbrooke s Hospital, Hills Rd, Cambridge, CB2 2XY, United Kingdom
    Infect Immun 75:852-60. 2007
    ..major challenge Th1 response compared to the Th2/T(reg) response. Thus, TRYP DNA/TRYP MVA, but not TRYP DNA alone, provides long-term protection against murine leishmaniasis...
  67. ncbi Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth
    Dexter Seto
    Kapiolani Medical Center for Women and Children, Honolulu, HI 96826, USA
    Pediatr Infect Dis J 21:793-5. 2002
    ..Although nearly one-half had become seronegative, all retained robust immunologic memory and rapidly regained a protective anti-HBs titer of at least 10 mIU/ml after booster vaccination...
  68. ncbi Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence
    U Heininger
    University Children s Hospital, Division for Pediatric Infectious Diseases and Vaccinology, Basel, Switzerland
    Vaccine 25:1055-63. 2007
    ....
  69. ncbi Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
    K G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Lancet 357:1937-43. 2001
    ..We did an observer-blind, phase I, randomised trial in healthy volunteers to assess safety, tolerability, and antigenicity of MF59-adjuvanted and non-adjuvanted vaccines...
  70. ncbi Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost
    Lasse Vinner
    Department of Virology, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen S, Denmark
    J Gen Virol 84:203-13. 2003
    ..The demonstrated humoral and cellular immunogenicities of these HIV Bx08 Env vaccines in non-human primates encourages their further development as one component in candidate HIV vaccines for humans...
  71. ncbi DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children
    Jose Ignacio Santos
    Departamento de Medicina Experimental, Facultad de Medicina UNAM and Conrejo Nacional de Vacunación, Ministry of Health, Mexico
    Vaccine 20:1887-93. 2002
    ..These results suggest that the combination of DTPw-HB and Hib vaccines provides an effective means for increasing vaccine coverage in childhood vaccination programmes...
  72. pmc Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors
    Danilo R Casimiro
    Department of Viral Vaccine Research, Merck Research Laboratories, Merck and Co, 770 Sumneytown Pike, West Point, PA 19486, USA
    J Virol 78:11434-8. 2004
    ..The heterologous Ad5 priming-poxvirus boosting approach may have potential utility in humans as a means of inducing high levels of cellular immunity...
  73. ncbi Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy
    Taraz Samandari
    Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Pediatrics 120:e373-81. 2007
    ..The duration of protection provided by hepatitis B vaccination is unknown, but the presence of immune memory can be evaluated indirectly by measuring the immune response to a booster dose of vaccine...
  74. ncbi Competition between CTL narrows the immune response induced by prime-boost vaccination protocols
    Michael J Palmowski
    Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 168:4391-8. 2002
    ..Our findings define a novel vaccination strategy optimized for the induction of an effective polyvalent cytotoxic response...
  75. pmc Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial
    Mecky Matee
    Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania
    J Infect Dis 195:118-23. 2007
    ..Most new tuberculosis vaccines will be administered as a booster to subjects primed with bacille Calmette-Guérin (BCG) during childhood...
  76. ncbi Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    Rama Rao Amara
    Vaccine Research Center, Yerkes Regional Primate Research Center, Emory University, 954 Gatewood Road NE, Atlanta, GA 30329, USA
    Vaccine 20:1949-55. 2002
    ..These highly promising findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the AIDS epidemic...
  77. ncbi Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population
    Marie J Estcourt
    John Curtin School of Medical Research, Australian National University, Canberra, ACT 2610, Australia
    Int Immunol 14:31-7. 2002
    ..Strategies that generate specific T cells of high avidity, optimizing early detection of infected cells, offer new hope for effective prophylaxis and immunotherapy...
  78. ncbi Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis
    D J Balestra
    Department of Medicine, Veterans Affairs Medical and Regional Office Center, White River Junction, VT 05009
    J Gen Intern Med 8:405-12. 1993
    ....
  79. ncbi Prime-boost immunization strategies for infectious diseases
    Helen McShane
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, UK
    Curr Opin Mol Ther 4:23-7. 2002
    ..Prime-boost immunization strategies involve using two different vaccines, each encoding the same antigen, some weeks apart. Such strategies have been shown to enhance cellular immunity in several different animal and disease models...
  80. ncbi [Why are boosters no longer necessary for protection against hepatitis B?]
    Claire Anne Siegrist
    Centre de vaccinologie et d immunologie néonatale, Universite de Geneve, C M U, 1211 Geneve 4, Suisse
    Rev Prat 54:509-11. 2004
    ..This resulted into a change of initial recommendations, which now highlight that booster doses are unnecessary in immunocompetent persons after a complete course of vaccination...
  81. pmc Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques
    W O Rogers
    Malaria Program, Naval Medical Research Center, Silver Spring, Maryland 20910, Bethesda, Maryland 20889, USA
    Infect Immun 69:5565-72. 2001
    ..This model will be important in preclinical vaccine development...
  82. ncbi Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination
    Ian T Williams
    Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30030, USA
    Pediatr Infect Dis J 22:157-63. 2003
    ..Few studies have examined the long term persistence of antibody after hepatitis B immunization beginning at birth and the response to a subsequent challenge with a booster dose of vaccine...
  83. ncbi Hepatitis B vaccine -- do we need boosters?
    J E Banatvala
    Clinical Virology, Guys Kings and St Thomas School of Medicine and Dentistry, Clinical Virology, London, UK
    J Viral Hepat 10:1-6. 2003
    ..If implemented, this recommendation will have considerable cost benefits world-wide...
  84. ncbi Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK
    Maria J Ramiro
    Centro de Investigaciones Biologicas, Velazquez 144, CSIC, Madrid 28006, Spain
    Vaccine 21:2474-84. 2003
    ..This type of DNA/rVV prime/boost immunization approach may have utility against visceral leishmaniasis in dogs...
  85. pmc Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen
    William O Rogers
    Malaria Program, Naval Medical Research Center, Silver Spring, Maryland 20910, USA
    Infect Immun 70:4329-35. 2002
    ..These findings demonstrate that a multistage, multiantigen, DNA priming and poxvirus boosting vaccine regimen can protect nonhuman primates from an otherwise lethal malaria sporozoite challenge...
  86. ncbi SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
    Patrick C Y Woo
    Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital, Hong Kong
    Vaccine 23:4959-68. 2005
    ..The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems...
  87. ncbi Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity
    Claire L Hutchings
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Immunol 175:599-606. 2005
    ....
  88. ncbi DNA vaccine for rabies: relevance of the trans-membrane domain of the glycoprotein in generating an antibody response
    Archana Rath
    Gamete Antigen Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India
    Virus Res 113:143-52. 2005
    ..The present results demonstrate that a DNA vaccine encoding the full-length sequence of the ectodomain plus TD of the mature native RV-G is capable of expressing an 'ideal' immunogen to produce RVNA titers...
  89. ncbi A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis
    Poonam Tewary
    School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
    J Infect Dis 191:2130-7. 2005
    ..We describe the effectiveness of a prime-boost vaccination regimen using the open-reading frame (ORFF) gene from the LD1 locus of Leishmania donovani...
  90. pmc Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates
    Sampa Santra
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P O Box 15732, Boston, MA 02215, USA
    J Virol 79:6516-22. 2005
    ..Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection...
  91. ncbi Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma
    Fernando Abaitua
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Campus Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
    Virus Res 116:11-20. 2006
    ..The increment of the CD8+ T cell response was higher in a DNA/MVA prime/boost protocol. Thus, the immune response of MVA vectors can be improved with the co-delivery of the cytokines IFN-gamma or IL-12...
  92. ncbi Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18
    Ma Mingxiao
    Genetic Engineering Laboratory, Academy of Military Medical Sciences, Changchun 130062, PR China
    Antiviral Res 76:59-67. 2007
    ..The results demonstrate the potential viability of a DNA vaccine in the control and prevention of FMDV infections...
  93. ncbi Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination
    Rui Ma
    Department of Immunology, Zhongshan School of Medicne, Sun Yat Sen University, Guangzhou, People s Republic of China
    Biochem Biophys Res Commun 361:537-42. 2007
    ..Taken together, our results imply that CpG ODN and R-848 may be the candidates as adjuvants for use in prophylactic and therapeutic hepatitis B vaccine...
  94. ncbi Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120
    Farley Cleghorn
    Center for HIV AIDS, Constella Futures, Washington, DC, USA
    J Acquir Immune Defic Syndr 46:222-30. 2007
    ..vCP1452 was administered alone or with a heterologous boost of MN rgp120 glycoprotein. The trial was pivotal in deciding whether these vaccines advanced to phase 3 efficacy trials...
  95. ncbi DNA priming and killed virus boosting vaccination strategy can augment the immune response to pseudorabies virus
    Z H Chen
    College of Veterinary Medicine, China Agricultural University, Beijing, China
    Acta Virol 51:163-70. 2007
    ..The results suggested that DNA priming followed by KV vaccine boosting could enhance the antibody response and cellular immunity against PRV infection in mice...
  96. ncbi Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C
    Wendy A Burgers
    Institute of Infectious Disease and Molecular Medicine and Division of Medical Virology, Department of Clinical Laboratory Sciences, University of Cape Town, Cape Town, South Africa
    AIDS Res Hum Retroviruses 24:195-206. 2008
    ..An accompanying paper describes the immunogenicity of SAAVI MVA-C when given in combination with SAAVI DNA-C...
  97. ncbi A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice
    Enid Shephard
    Institute of Infectious Disease and Molecular Medicine and Division of Medical Virology, Department of Clinical Laboratory Sciences, University of Cape Town, Cape Town, South Africa
    AIDS Res Hum Retroviruses 24:207-17. 2008
    ..The demonstration that these vaccines induce potent cellular immune responses merits their testing in clinical trials...
  98. ncbi Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity
    Jin Su
    BioTherapeutics Research Group, Robarts Research Institute, Canada Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada, N6A 5K8
    Virology 375:48-58. 2008
    ..This vaccine strategy may facilitate the generation of an efficacious vaccine for HIV, and other chronic diseases that require enhanced cell-mediated immunity, including HCV and metastatic cancer...
  99. ncbi Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model
    Silvia I Cazorla
    Cátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral IDEHU, CONICET UBA, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Junin 956 4to P, 1113 Buenos Aires, Argentina
    Vaccine 26:1999-2009. 2008
    ..This prime-boost regimen appears promising for further development, since warranted survival, provided efficient control of parasite load and restricted inflammatory myopathy...
  100. pmc Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza
    Victor C Huber
    Deparment of Infectious Disease, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Clin Vaccine Immunol 13:981-90. 2006
    ..This study details separate but important roles for both IgG1 and IgG2a expression in vaccination against influenza and argues for the development of vaccine regimens that stimulate and measure expression of both antibody isotypes...
  101. ncbi Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever
    D B Wallace
    Onderstepoort Veterinary Institute, Onderstepoort, South Africa
    Vaccine 24:7181-9. 2006
    ..Vaccinated sheep sero-converted for both viruses and were protected against RVFV challenge, however, neither the immunised or negative control animals showed any significant reactions to the virulent SPV challenge...

Research Grants67

  1. Group 1 CD1 in Infectious Disease and T Cell Development
    Chyung Ru Wang; Fiscal Year: 2013
    ..Mtb lipids elicit group 1 CD1-restricted Mtb- lipid antigen-specific T cell responses in hCD1Tg mice, and secondary immunization induces more rapid responses than primary immunization...
  2. Regulation of murine neonatal Th2 function
    REBECCA D ADKINS; Fiscal Year: 2010
    ..This idea is supported by our findings that the function of peripheral CD4+ cells in neonates resembles that of RTE in adults. ..
  3. Complement as an Adjuvant in Polysaccharide Immunity
    SAMUEL TEST; Fiscal Year: 2003
    ..pneumoniae will be prepared and evaluated in different strains of mice. These experiments should provide new insights into the immune response to conjugate vaccines and facilitate future efforts to improve vaccine efficacy. ..
  4. AGING AND IMMUNITY IN TUBERCULOSIS
    Ian Orme; Fiscal Year: 2002
    ....
  5. Chronic Tuberculosis: Latent or Dynamic
    Ian Orme; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  6. Role of DAP12 in type 1 anti-mycobacterial immunity
    Zhou Xing; Fiscal Year: 2005
    ..We strongly believe that our studies will provide new insights into the mechanisms of type 1 anti-microbial immunity and novel targets for immune modulation. ..
  7. Polyvalent DNA Plus Protein HIV Vaccines
    Shan Lu; Fiscal Year: 2010
    ..This will allows us to effectively screen a large number of unique primary Env antigens to formulate the effective polyvalent HIV vaccines for the next phase of clinical testing. ..
  8. STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE
    Ian Orme; Fiscal Year: 2004
    ..abstract_text> ..
  9. Vaccine Induced Mucosal Protection Against TB Infection
    DANIEL HOFT; Fiscal Year: 2005
    ..Prime/boosting strategies found to prevent BCG infection after aerosol challenges will be studied for the ability to prevent infection with virulent M. tuberculosis by aerosol challenge. ..
  10. Multi-gene plague vaccine with expanded protection
    Shan Lu; Fiscal Year: 2004
    ..This project will employ the most advanced DNA immunization technology in combination with small-scale protein production to quickly develop potential subunit-based plague vaccine products. ..
  11. Guinea pig model for TB vaccine evaluations
    Ian Orme; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  12. DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSIS
    Ian Orme; Fiscal Year: 2006
    ..The proposed work will draw upon the broad expertise of various members of the Mycobacteria Research Laboratories at Colorado State University, as well as several eminent consultants and advisers. ..
  13. Immune Responses to Biodefense Vaccines Early in Life
    Marcela F Pasetti; Fiscal Year: 2010
    ..It will also provide knowledge to better understand the mechanisms mediating neonatal-infant immunity to develop more effectivevaccines to prevent diseases early in life. ..
  14. TRYPANOSOMA CRUZI MUCOSAL & SYSTEMIC PROTECTIVE IMMUNITY
    DANIEL HOFT; Fiscal Year: 2008
    ..Chemokine and/or integrin receptor expression will be studied by flow cytometry and RT-Real-Time PCR, and the in vivo effects of defective chemokine and integrin binding and/or signaling will be evaluated. [unreadable] [unreadable]..
  15. Characterization of the M. tuberculosis phagosome
    MARCUS HORWITZ; Fiscal Year: 2007
    ..These experiments will advance our understanding of the cell biology and pathogenic mechanisms of M. tuberculosis and facilitate the development of new strategies to combat tuberculosis. [unreadable] [unreadable]..
  16. Novel Antimicrobial Agents Against M. tuberculosis
    MARCUS HORWITZ; Fiscal Year: 2008
    ..mammalian GS, and test the toxicity of the analogs in mice. 2) Test the novel MSO analogs for their capacity to inhibit M. tuberculosis growth in broth culture, in human macrophages, and in guinea pigs. ..
  17. Neonatal Immunization with Acellular Pertussis Vaccines
    Natasha Halasa; Fiscal Year: 2007
    ....
  18. CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITY
    Daniel Smith; Fiscal Year: 2007
    ..unreadable]..
  19. Immunotherapy for Pancreatic Amylin Aggregates in Diabetes
    Einar Sigurdsson; Fiscal Year: 2008
    ..These studies could lead to novel treatments for type-2 diabetes. [unreadable] [unreadable] [unreadable]..
  20. Genomics of Susceptibility to Urinary Tract Infections
    WALTER HOPKINS; Fiscal Year: 2007
    ..coli strains or non-E, coil bacteria. These objectives will be accomplished using a well-established mouse model of ascending UTI, genetic linkage analysis, and evaluation of resistance to uropathogens in congenic mice. ..
  21. Dynamics of TCR Repertoire Following Thymus Transplant
    MARY MARKERT; Fiscal Year: 2008
    ..These findings will have application to thymus and bone marrow transplantation for immunodeficiency and cancer. ..
  22. Immunobiological Role of Fertilization Antigen(FA-1)
    RAJESH NAZ; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  23. Reconstitution of Protective CMV Immunity and Immune Regulation After HAART
    Adriana Weinberg; Fiscal Year: 2008
    ..These analyses will define the role of TREG in the inadequate CMV immune reconstitution of HAART recipients. [unreadable] [unreadable] [unreadable] [unreadable]..
  24. T-Cell Responses Predict Influenza Risk in Older Adults
    Janet E McElhaney; Fiscal Year: 2010
    ..3) Test heat shock proteins (Hsp) as potential vaccine adjuvants to enhance the CTL response to vaccination. ..
  25. Memory T cell subsets and pulmonary immunity
    David L Woodland; Fiscal Year: 2010
    ....
  26. Poly-functional analyses of vaccine-induced T cell responses
    Guido Ferrari; Fiscal Year: 2010
    ..Overall, these findings will shed new insights on the importance and fate of vaccine-induced T cell responses in controlling HIV-infection. ..
  27. Studies on the Eppin family of proteins on chromosome 20
    MICHAEL G O apos RAND; Fiscal Year: 2010
    ..This aim will test the hypothesis that anti-Eppin antibodies disrupt Eppin's modulation of PSA activity. ..
  28. HIV Testing and Women's Attitudes on HIV Vaccine Trials
    Gregory D Zimet; Fiscal Year: 2010
    ..abstract_text> ..
  29. A TB Vaccine for AIDS Patients
    MARCUS AARON HORWITZ; Fiscal Year: 2010
    ..Finally, we shall confirm the safety of the new recombinant vaccines in an immunocompromised animal host (SCID mouse model). ..
  30. Tuberculosis Diagnostics: Towards More Precise Testing in Children
    Joseph Bellanti; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  31. Dose Study of thymus Transplantation
    MARY MARKERT; Fiscal Year: 2007
    ..Abstract Not Provided. ..
  32. Role of E. coli Virulence Factors in Chronic Prostate Infection and Inflammation
    WALTER HOPKINS; Fiscal Year: 2008
    ..coli genes play a direct or indirect role in development of prostatic lesions. Results of these studies can lead to new methods to prevent or treat chronic bacterial prostatitis. [unreadable] [unreadable] [unreadable]..
  33. Respiratory Immunity Against Agents of Bioterrorism
    STEVEN MIZEL; Fiscal Year: 2008
    ....
  34. Regulation of CD8+ T cell responses to influenza virus
    DAVID WOODLAND; Fiscal Year: 2007
    ..abstract_text> ..
  35. Papillomavirus E2 as a cervical/anal cancer drug target
    Janet Brandsma; Fiscal Year: 2005
    ..Vectors containing a conditional wild-type CRPV E2 transgene will be used to determine the effects of E2 overexpression. ..
  36. Parathyroid and Thymus Transplants in DiGeorge Syndrome
    MARY MARKERT; Fiscal Year: 2005
    ..Indirect allorecognition as a mechanism of graft rejection will be assessed by ELISpot. The third aim will assess safety and tolerability. ..
  37. Acellular vaccines against Francisella tularensis
    Wayne Conlan; Fiscal Year: 2005
    ..It is expected that the findings from the proposed studies will be applicable to the development of acellular vaccines against other intracellular respiratory pathogens such as Mycobacterium tuberculosis, and Chlamydia pneumoniae. ..
  38. Chimeric Adenovirus Vaccine Vectors for HIV/SIV
    DAN BAROUCH; Fiscal Year: 2005
    ..Within the two-year time frame of this award, sufficient data will be generated with candidate chimeric rAd vaccines to justify further vaccine/challenge studies in rhesus monkeys. ..
  39. URINARY TRACT INFECTIONS--IMMUNE BASIS OF SUSCEPTIBILITY
    WALTER HOPKINS; Fiscal Year: 2003
    ....
  40. IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
    Paul Chapman; Fiscal Year: 2003
    ..This close mentoring relationship reflects our current teaching paradigm. The grant award will provide the PI with more time to conduct the clinical trials and to mentor additional beginning clinical investigators. ..
  41. NOVEL THERAPEUTIC TARGETS IN RHEUMATOID ARTHRITIS
    EUGENE ST CLAIR; Fiscal Year: 2003
    ..St.Clair with outstanding clinical research opportunities and educational experiences for his trainees. ..
  42. M TUBERCULOSIS GLUTAMINE SYNTHETASE EXPORT & INHIBITION
    MARCUS HORWITZ; Fiscal Year: 2002
    ..tuberculosis glutamine synthetase, they hope to develop more active entities than the parent compound and thereby to develop a new antibiotic against M. tuberculosis. ..
  43. COUNTER REGULATION OF STRESS MEDIATED IMMUNOSUPPRESSION
    David Padgett; Fiscal Year: 2002
    ..The long-term goals should provide insight into the relationships between the nervous, endocrine, and immune systems and how inflammatory immune responses can be regulated at many different central and peripheral levels. ..
  44. SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS
    Alan Cross; Fiscal Year: 2002
    ..These studies will define a new mechanism for a rapidly adaptable, temporally- restricted local response to inflammation. This proposal will provide new targets and additional approaches to the treatment of inflammation. ..
  45. INTERFERON Y MEDIATES ANTI E COLI DEFENSES AND SEPSIS
    Alan Cross; Fiscal Year: 2001
    ..The demonstration of a spectrum of responses to LPS in these studies may identify the earliest changes in cytokine responses that predict the development of sepsis. ..
  46. IMMUNIZATION AGAINST URINARY TRACT INFECTION
    DAVID UEHLING; Fiscal Year: 2001
    ..2. Utilize an animal model to clarify the immunologic basis for the increased resistance to UTI following vaginal immunization and to evaluate adjuvants and vaccination regimes that optimize immunogenicity and efficacy of UTI vaccines. ..
  47. IMMUNE CONTROL OF CAE LENTIVIRUS
    Donald Knowles; Fiscal Year: 2005
    ..Therefore, the second objective of this proposal is to evaluate virus replication following CAEV challenge of goats co-immunized with plasmid DNA expressing CAEV env and tat genes and caprine IFN. ..
  48. Familial IgA Nephropathy: Genetic and Metabolic Studies
    Jiri Mestecky; Fiscal Year: 2006
    ..abstract_text> ..
  49. Whole Autologous SIV Vaccine Using Dendritic Cells
    SIMON BARRATT BOYES; Fiscal Year: 2006
    ....
  50. Bacterial Vaccine Antigen Discovery
    LAWRENCE PAOLETTI; Fiscal Year: 2006
    ..Aim 2). Findings from these studies utilizing this unique approach to vaccine antigen discovery could be directly applied to other bacterial pathogens. ..
  51. Novel broad spectrum vaccination against influenza
    Petr Ilyinskii; Fiscal Year: 2006
    ..The overall aim of this project is to demonstrate better protective effect or/and enhanced immune response using modified influenza proteins as immunogens compared to wild-type viral proteins. ..
  52. Phase II trial of 17-AAG in melanoma patients
    Paul Chapman; Fiscal Year: 2007
    ..post-treatment specimens, clinically responding tumors vs. non-responding tumors, and mutant BRAF vs. wild-type BRAF tumors. [unreadable] [unreadable] [unreadable]..
  53. Protective Immune Responses in HIV-1 Exposed Infants
    Carey Farquhar; Fiscal Year: 2006
    ..Kreiss and John, will prepare her for the complex data analysis required by this study and contribute substantially to the development of her career as an independent clinical investigator. ..
  54. Interventions to Increase HBV Vaccination in STD Clinics
    Gregory Zimet; Fiscal Year: 2006
    ..The relationships of the interventions, socio-demographics, attitudes and behaviors to the outcome measures will be assessed with multiple logistic regression (MLR) and path analysis via structural equation modeling. ..
  55. PERIODONTAL DISEASE:ROLE OF ABERRANT Ig GLYCOSYLATION
    Jiri Mestecky; Fiscal Year: 2006
    ..Results of these studies will generate information concerning previously unexplored inflammatory pathways that participate in the development of PD. ..
  56. VZV Receptors and Infective Mechanisms
    Anne Gershon; Fiscal Year: 2007
    ..It may also make it possible to develop a safer and more efficacious vaccine. ..
  57. Protective cellular immune responses in HIV-1 discordant couples
    Carey Farquhar; Fiscal Year: 2010
    ....
  58. PEDIATRICS AIDS CLINICAL TRIALS GROUP
    Anne Gershon; Fiscal Year: 2006
    ..We have competent, outstanding staff whose aim is not only to provide compassionate medical care to HIV-infected patients but also to perform meaningful and useful research on prevention and treatment of HIV infection. ..
  59. Biodefense vaccine for pandemic influenza
    Lawrence Smith; Fiscal Year: 2005
    ..FINAL MILESTONE 3: Completion of Aim 2 and completion of IND ..
  60. Design and Use of HIV V3 Mimetic Immunogens
    Susan Zolla Pazner; Fiscal Year: 2008
    ..Finally, in Aim 3, we will examine how the intra- and inter-molecular interactions of gpl20 and gp41 affect neutralization sensitivity to anti-V3 mAbs. ..
  61. Activation of inflammatory cells by flagellin
    STEVEN MIZEL; Fiscal Year: 2006
    ..Furthermore, the proposed studies should also provide insights into the factors that regulate TLR signaling and allow for complex patterns of host cell response. ..
  62. Effects of Probiotic Lactobacilli on Rotavirus Immunity
    Lijuan Yuan; Fiscal Year: 2006
    ..The findings from this study will also facilitate an understanding of the potential adjuvant effects of probiotics for development of more effective vaccines against rotavirus and other enteric virus-induced diseases. ..